In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
As of close of business last night, Health Catalyst Inc’s stock clocked out at $2.64, up 1.15% from its previous closing price of $2.61. In other words, the price has increased by $1.15 from its previous closing price. On the day, 0.62 million shares were traded. HCAT stock price reached its highest trading level at $2.685 during the session, while it also had its lowest trading level at $2.55.
Ratios:
To gain a deeper understanding of HCAT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.86 and its Current Ratio is at 1.86. In the meantime, Its Debt-to-Equity ratio is 0.52 whereas as Long-Term Debt/Eq ratio is at 0.50.
Cantor Fitzgerald Downgraded its Overweight to Neutral on August 08, 2025, while the target price for the stock was maintained at $4.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 05 ’25 when Landry Benjamin sold 27,425 shares for $2.64 per share. The transaction valued at 72,328 led to the insider holds 100,000 shares of the business.
Larson-Green Julie sold 47,997 shares of HCAT for $128,349 on Dec 04 ’25. The Director now owns 73,573 shares after completing the transaction at $2.67 per share. On Dec 05 ’25, another insider, BENJAMIN LANDRY, who serves as the Officer of the company, bought 27,425 shares for $2.69 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HCAT now has a Market Capitalization of 186729536 and an Enterprise Value of 267308528. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.38. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.59 while its Price-to-Book (P/B) ratio in mrq is 0.56. Its current Enterprise Value per Revenue stands at 0.846 whereas that against EBITDA is -15.867.
Stock Price History:
The Beta on a monthly basis for HCAT is 1.69, which has changed by -0.67415726 over the last 52 weeks, in comparison to a change of 0.13042927 over the same period for the S&P500. Over the past 52 weeks, HCAT has reached a high of $8.52, while it has fallen to a 52-week low of $2.02. The 50-Day Moving Average of the stock is -6.53%, while the 200-Day Moving Average is calculated to be -25.70%.
Shares Statistics:
It appears that HCAT traded 636.87K shares on average per day over the past three months and 745610 shares per day over the past ten days. A total of 70.62M shares are outstanding, with a floating share count of 66.06M. Insiders hold about 6.60% of the company’s shares, while institutions hold 78.14% stake in the company. Shares short for HCAT as of 1764288000 were 6028208 with a Short Ratio of 9.47, compared to 1761868800 on 6203840. Therefore, it implies a Short% of Shares Outstanding of 6028208 and a Short% of Float of 9.71.
Earnings Estimates
Investors are keenly observing as 8.0 analysts analyze and rate. The current performance of Health Catalyst Inc (HCAT) in the stock market.The consensus estimate for the next quarter is $0.08, with high estimates of $0.15 and low estimates of $0.03.
Analysts are recommending an EPS of between $0.25 and $0.18 for the fiscal current year, implying an average EPS of $0.21. EPS for the following year is $0.35, with 10.0 analysts recommending between $0.62 and $0.21.
Revenue Estimates
In. The current quarter, 11 analysts expect revenue to total $73.94M. It ranges from a high estimate of $75.04M to a low estimate of $73.5M. As of. The current estimate, Health Catalyst Inc’s year-ago sales were $79.61MFor the next quarter, 11 analysts are estimating revenue of $74.21M. There is a high estimate of $76.4M for the next quarter, whereas the lowest estimate is $71.96M.
A total of 12 analysts have provided revenue estimates for HCAT’s current fiscal year. The highest revenue estimate was $311.49M, while the lowest revenue estimate was $309.9M, resulting in an average revenue estimate of $310.26M. In the same quarter a year ago, actual revenue was $306.58MBased on 12 analysts’ estimates, the company’s revenue will be $302.08M in the next fiscal year. The high estimate is $307.5M and the low estimate is $298.1M.
